MV
Therapeutic Areas
Immutep Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Eftilagimod alfa (efti) | 1st & 2nd line Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 |
| IMP761 | Autoimmune Diseases | Phase 1 (planned) |
| IMP731 | Ulcerative Colitis | Phase 2 |
| LAG525 (ieramilimab) | Various cancers (Novartis partnership) | Multiple Phases |
| Novel Small Molecule LAG-3 Inhibitor | Oncology | Early Research |